Founded in 2013, Highlight Therapeutics is a Spanish biotech focused on innovating immunotherapies for cancer, particularly skin tumours. Its lead investigational compound, BO-112, is a double-stranded RNA therapy that mimics viral infection to activate the immune system against tumour cells. BO-112 is currently in a Phase 2b clinical trial for basal cell carcinoma and has already shown activity in aggressive melanoma, with plans to expand into additional tumour types. The company collaborates closely with the Spanish National Cancer Research Center (CNIO), from which the BO-112 programme originated. Fresh funding will allow Highlight to accelerate clinical development, strengthen its team, and broaden its pipeline. Recent executive hires, including Chief Business Officer Abel Riera, signal a push toward business development and future partnerships. The firm positions itself as a leader in accessible, transformative cancer therapies backed by strong scientific foundations.

Total raised

$45M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2025